Effect of guaifenesin on mucin production, rheology, and mucociliary transport in differentiated human airway epithelial cells

Experimental Lung Research

Volumn 37, Issue 10, 2011, Pages 606-614

  Seagrave, Jeanclare ^a   Albrecht, Helmut ^b   Park, Yong Sung ^c   Rubin, Bruce ^d   Solomon, Gail ^b   Kim, K Chul ^c  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b RECKITT BENCKISER   (United Kingdom)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

In vitro; MUC5AC; Mucus; Rheology; Viscoelasticity

Indexed keywords

GUAIFENESIN; MUCIN; MUCIN 5AC;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL LYSATE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FLOW KINETICS; FLOW MEASUREMENT; HUMAN; HUMAN CELL; MUCOCILIARY TRANSPORT; PRIORITY JOURNAL; PROTEIN SECRETION; RESPIRATORY EPITHELIUM;

BRONCHI; CELL DIFFERENTIATION; CELLS, CULTURED; EPITHELIAL CELLS; GUAIFENESIN; HUMANS; MUCIN 5AC; MUCINS; MUCOCILIARY CLEARANCE; MUCUS; RHEOLOGY; TRACHEA; VISCOSITY;

EID: 81455138221     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2011.623116     Document Type: Article

References (35)

1. Melton L: Does mucus hypersecretion matter in airway disease? Novartis Found Symp. 2002;10:2-4.
2. Nasra J, Belvisi MG:Modulation of sensory nerve function and the cough reflex: understanding disease pathogenesis. Pharmacol Ther. 2009;124:354-375.
3. Ayres PJW: Experimental and clinical methodologies in efficacy of expectorants using the example of guaifenesin. In: Loew D, Rietbrock N, eds. Phytopharmaka III. Darmstadt, Germany: Steinkopf Verlag; 1997:151-160.
4. Thomson ML, Pavia D, McNicol MW: A preliminary study of the effect of guaiphenesin onmucociliary clearance from the human lung. Thorax 1973;28:742-747.
5. RogersDF: Mucoactive agents for airwaymucus hypersecretory diseases. Respir Care. 2007;52:1176-1193.
6. Food and Drug Administration: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-thecounter human use, final rule. Fed Regist. 1989;54:8494.
7. Chodosh S, Medici TC, Enslein K: Objective sputum changes associated with glyceryl guiacolate in chronic bronchial diseases. Bull Physiopathol Respir. 1973;9:452-456.
8. Irwin RS, Boulet LP, Cloutier MM, Fuller R, Gold PM, Hoffstein V, et al.: Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest. 1998;114:133S-181S.
9. Naito SI,MizutaniM, Osumi S, Mikawa T, Sekishiro K, Nakao K, et al.: Biopharmaceutical studies on guaiacol glyceryl ether and related compounds. V. J Pharm Sci. 1972;61:1212-1215.
10. Kagan L, Lavy E, Hoffman A: Effect of mode of administration on guaifenesin pharmacokinetics and expectorant action in the rat model. Pulm Pharmacol Ther. 2009;22:260-265.
11. Rossberg F, Luther D: Animal experiment on the absorption, distribution and elimination of C14- and H3-labelled guaiacolglyceryl- ether. Acta Biol Med Ger. 1971;26:331-339.
12. Vandenheuvel WJ, Smith JL, Silber RH: -(2- Methoxyphenoxy)lactic acid, the major urinary metabolite of glyceryl guaiacolate in man. J Pharm Sci. 1972;61:1997-1998.
13. Kauert G, von ML, Drasch G: Investigations of guaifenesine metabolism with gas chromatography-mass spectrometry. Arch Toxicol. 1980;45:149-159. (Pubitemid 10066727)
14. Aluri JB, Stavchansky S: Determination of guaifenesin in human plasma by liquid chromatography in the presence of pseudoephedrine. J Pharm Biomed Anal. 1993;11:803-808. (Pubitemid 23294670)
15. Bennet W, Kala A, Zeman K, Wu J, Henderson A, Albrecht H, et al.: Effect of oral guaifenesin (Mucinex 1200mg) on mucociliary clearance from the lungs of healthy non-smoking adults. Presented at European Respiratory Society Annual Meeting, Sept 18-22, 2010; 251309.
16. Wawrose SF, Tami TA, Amoils CP: The role of guaifenesin in the treatment of sinonasal disease in patients infected with the human immunodeficiency virus (HIV). Laryngoscope. 1992;102:1225-1228.
17. Rosen EJ, Calhoun KH: Alterations of nasal mucociliary clearance in association with HIV infection and the effect of guaifenesin therapy. Laryngoscope. 2005;115:27-30. (Pubitemid 40096521)
18. Dicpinigaitis PV, Gayle YE: Effect of guaifenesin on cough reflex sensitivity. Chest. 2003;124:2178-2181. (Pubitemid 38010587)
19. Sisson JH, Yonkers AJ, Waldman RH: Effects of guaifenesin on nasalmucociliary clearance and ciliary beat frequency in healthy volunteers. Chest. 1995;107:747-751.
20. Rubin BK: An in vitro comparison of the mucoactive properties of guaifenesin, iodinated glycerol, surfactant, and albuterol. Chest. 1999;116:195-200. (Pubitemid 29340282)
21. KesimerM, Kirkham S, Pickles RJ, Henderson AG, Alexis NE, DeMaria G, et al.: Tracheobronchial air-liquid interface cell culture: a model for innate mucosal defense of the upper airways? Am J Physiol Lung Cell Mol Physiol. 2009;296:L92-L100.
22. Lu W, Lillehoj EP, Kim KC: Effects of dexamethasone on Muc5ac mucin production by primary airway goblet cells. Am J Physiol Lung Cell Mol Physiol. 2005;288:52-58.
23. Bautista MV, Chen Y, Ivanova VS, Rahimi MK, Watson AM, Rose MC: IL-8 regulates mucin gene expression at the posttranscriptional level in lung epithelial cells. J Immunol. 2009;183:2159-2166.
24. Chang JH, Song KJ, Kim HJ, Kim JH, Kim NH, Kim KS: Dietary polyphenols affect MUC5AC expression and ciliary movement in respiratory cells and nasal mucosa. AmJ Rhinol Allergy. 2010;24:e59-e62.
25. Chen Y, Zhao YH, Wu R: Differential regulation of airway mucin gene expression and mucin secretion by extracellular nucleotide triphosphates. Am J Respir Cell Mol Biol. 2001;25:409-417. (Pubitemid 33037672)
26. Foster WM, Adler KB, Crews AL, Potts EN, Fischer BM, Voynow JA:MARCKS-related peptide modulates in vivo the secretion of airwayMuc5ac. Am J Physiol Lung Cell Mol Physiol. 2010;299:345-352.
27. Fujisawa T, Velichko S, Thai P, Hung LY, Huang F, Wu R: Regulation of airway MUC5AC expression by IL- 1{beta} and IL-17A; the NF-{kappa}B paradigm. J Immunol. 2009;118.:6236-6243.
28. Kim HJ, Park SH, Park SY, Moon UY, Lee BD, Yoon SH, et al.: Epigallocatechin-3-gallate inhibits interleukin-1betainducedMUC5AC gene expression and MUC5AC secretion in normal human nasal epithelial cells. J Nutr Biochem. 2008;19:536-544.
29. Kim S, Lewis C, Nadel JA: CCL20/CCR6 feedback exaggerates epidermal growth factor receptor-dependent MUC5AC mucin production in human airway epithelial (NCI-H292) cells. J Immunol. 2011;186:3392-3400.
30. Nishimoto Y, Hisatsune A, Katsuki H, Miyata T, Yokomizo K, Isohama Y: Glycyrrhizin attenuates mucus production by inhibition of MUC5AC mRNA expression in vivo and in vitro. J Pharmacol Sci. 2010;113:76-83.
31. Rubin BK: Taxonomy of mucoactive medications. In: Rubin BK, van der Schans CP, eds. Therapy for Mucus Clearance Disorders. New York: Marcel Dekker; 2004:129-146.
32. Rose MC, Voynow JA: Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev. 2006;86:245-278.
33. Hovenberg HW, Davies JR, Carlstedt I: Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells. Biochem J. 1996;318:319-324. (Pubitemid 26283662)
34. Wickstrom C,Davies JR, EriksenGV, Veerman EC, Carlstedt I: MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem J. 1998;334(Pt 3):685-693. (Pubitemid 28457218)
35. Zuhdi AM, Piazza FM, Selby DM, Letwin N, Huang L, Rose MC:Muc-5/5ac mucin messenger RNA and protein expression is a marker of goblet cell metaplasia in murine airways. Am J Respir Cell Mol Biol. 2000;22:253-260. (Pubitemid 30343350)